Masanori Asada

Dr. Masanori Asada

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Digestive Endoscopy
Verified
Journal Article
Open access
PDF file
KFKoichi Fujita
Koichi Fujita
SYShujiro Yazumi
Shujiro Yazumi
HMHisakazu Matsumoto
Hisakazu Matsumoto
Masanori AsadaMasanori Asada
Masanori Asada
HNHiroko Nebiki
Hiroko Nebiki
FJfor the Bilio‐pancreatic Study Group of West Japan
for the Bilio‐pancreatic Study Group of West Japan
Objectives: The reported incidence of adverse events (AEs) in endoscopic retrograde cholangiopancreatography (ERCP) varies between 2.5% and 14%. The aim of this study was to evaluate the incidence and severity of AEs in biliary ERCP and to specify the risk factors and preventive measures for post‐ERCP pancreatitis (PEP).Methods: Patients with biliary disease with intact papilla were prospectively enrolled at 36 hospitals between April 2017 and March 2018. The primary outcomes were the incidence and severity of AEs.Results: A total of 16,032 ERCP procedures were performed at the 36 hospitals during the study period and 3739 patients were enrolled. The overall incidence of AEs was 10.1% and ERCP‐related mortality was 0.08%. PEP developed in 258 cases (6.9%), bleeding in 33 (0.9%), instrumental AEs in 17 (0.5%), infections in 37 (1.0%), cardiovascular AEs in eight (0.2%), pulmonary AEs in eight (0.2%), drug reaction AE in one (0.03%), pain in 15 (0.4%), and other AEs in 15 (0.4%). Multivariable analysis showed significant risk factors for PEP were: female of younger age, pancreatic guidewire‐assisted biliary cannulation, temporary guidewire insertion into the pancreatic duct, total procedure time >60 min, and post‐ERCP administration of non‐steroidal anti‐inflammatory drugs. Effective preventive measures were prophylactic pancreatic stenting (PPS) and epinephrine spraying onto the papilla.Conclusions: In patients with intact papilla who underwent biliary ERCP, the incidence of AEs was 10.1% and the mortality was 0.08%. PPS and epinephrine spraying may prevent PEP.Registration: This study was registered in the University Hospital Medical Information Network (UMIN000024820).

21 August 2007 in Helicobacter
Verified
Journal Article
Closed access
PDF file
TFToshiro Fukui
Toshiro Fukui
ANAkiyoshi Nishio
Akiyoshi Nishio
KOKazuichi Okazaki
Kazuichi Okazaki
KKKatsuhiro Kasahara
Katsuhiro Kasahara
KSKazuyuki Saga
Kazuyuki Saga
TCTsutomu Chiba
Tsutomu Chiba

3 April 2021 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
MTMasanori Tsujie
Masanori Tsujie
TITomohisa Iwai
Tomohisa Iwai
SKShoji Kubo
Shoji Kubo
TUTakashi Ura
Takashi Ura
EHEtsuro Hatano
Etsuro Hatano
CMChigusa Morizane
Chigusa Morizane
Fibroblast growth factor receptor gene alterations have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer that has a poor prognosis. This study evaluated the frequency of fibroblast growth factor receptor 2 fusions in clinical specimens from Japanese patients with iCCA. This study enrolled 116 patients who had histologically or cytologically confirmed adenocarcinoma and been diagnosed as relapsing after resection or with unresectable intrahepatic cholangiocarcinoma. We evaluated the frequency of fibroblast growth factor receptor 2 fusions-positive cells in their specimens using break-apart fluorescent in situ hybridization ‘for 114 patients who met the study protocol’. Of a total of 114 cases, six (5.3%) were identified as fibroblast growth factor receptor 2 fusions-positive with a high frequency (87% or more) of fibroblast growth factor receptor 2 fusions-positive tumour cells whereas the remainder, with the exception of three cases with indeterminate results, were identified as fibroblast growth factor receptor 2 fusions-negative. The patients’ baseline characteristics as well as their objective response rates, disease control rates, times to progression, and times to treatment failure with previous or ongoing first-line chemotherapy did not have any obvious relationship to the proportion of fibroblast growth factor receptor 2 fusions-positive case. Further detailed elucidation of fibroblast growth factor receptor 2 fusion status is expected to contribute to the development of promising therapeutic options for patients suffering from recurrent or unresectable intrahepatic cholangiocarcinoma.

17 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KMKazuya Matsumoto
Kazuya Matsumoto
HNHisashi Noma
Hisashi Noma
KFKoichi Fujita
Koichi Fujita
TTTakeshi Tomoda
Takeshi Tomoda
TOTakumi Onoyama
Takumi Onoyama
HKHirofumi Kawamoto
Hirofumi Kawamoto
The prognostic factors associated with severe-to-fatal post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) remain unclear despite the extensive number of studies on PEP. In total, 3739 ERCP patients with biliary disease with an intact papilla and indicated for ERCP were prospectively enrolled at 36 centers from April 2017 to March 2018. Those with acute pancreatitis diagnosed before ERCP, altered gastrointestinal anatomy, and an American Society of Anesthesiologists (ASA) physical status > 4 were excluded. Univariate and multivariate logistic regression analyses were performed on patient-related factors, operator-related factors, procedure-related factors, and preventive measures to identify potential prognostic factors for severe-to-fatal PEP. Multivariate analyses revealed pancreatic guidewire-assisted biliary cannulation (OR 13.59, 95% CI 4.21–43.83, p < 0.001), post-ERCP non-steroidal anti-inflammatory drug (NSAID) administration (OR 11.54, 95% CI 3.83–34.81, p < 0.001), and previous pancreatitis (OR 6.94, 95% CI 1.45–33.33, p = 0.015) as significant risk factors for severe-to-fatal PEP. Preventive measures included endoscopic biliary sphincterotomy (EST; OR 0.29, 95% CI, 0.11–0.79, p = 0.015) and prophylactic pancreatic stents (PPSs; OR 0.11, 95% CI, 0.01–0.87, p = 0.036). In biliary ERCP, pancreatic guidewire-assisted biliary cannulation, NSAID administration after ERCP, and previous pancreatitis were risk factors for severe-to-fatal PEP, whereas EST and PPS were significant preventive measures for severe-to-fatal PEP.

15 May 2007 in Respiration
Verified
Journal Article
Closed access
PDF file
SESatoru Ebihara
Satoru Ebihara
TETakae Ebihara
Takae Ebihara
SYShinsuke Yamanda
Shinsuke Yamanda
Masanori AsadaMasanori Asada
Masanori Asada
HAHiroyuki Arai
Hiroyuki Arai